Prostate Cancer Clinical Trial

Genomics in Michigan Impacting Observation or Radiation

Summary

To determine the impact of Decipher test results on adjuvant treatment decisions of high-risk post-RP patients with undetectable post-op prostate specific antigen (PSA) compared to clinical factors alone.

View Full Description

Full Description

This prospective, randomized trial will compare the receipt of adjuvant therapy for high-risk radical prostatectomy (RP) patients who undergo Decipher testing to those who do not. 350 subjects from within the statewide Michigan Urological Surgery Improvement Collaborative (MUSIC) will be randomized to either a Genomic Classifier (Decipher) or Usual-Care-Based (UC) strategy for a period of three months. If enrolled during the Genomic Classifier period, both subjects and their treating physician will be provided Decipher results and CAPRA-S scores. In the UC periods, CAPRA-S scores but not Decipher results will be provided.

The enrollment goal, initially and throughout the study, was to enroll 350 evaluable patients. During the study, the target accrual goal was raised to 550 patients to allow more flexibility among sites to achieve the enrollment goal of 350 evaluable patients.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Prostate cancer patients who have undergone radical prostatectomy
PSA < 0.1 ng/ml at enrollment

At least one of the following:

pT3 (seminal vesicle invasion or extraprostatic extension), or
Positive surgical margins
Radical prostatectomy within one year of enrollment

Exclusion Criteria:

Individuals who have any of the following will not be eligible to participate:

Have regional or distant metastatic disease
Received any radiation or hormone therapy (neo-adjuvant, adjuvant, or salvage)
Node positive

Study is for people with:

Prostate Cancer

Estimated Enrollment:

356

Study ID:

NCT02783950

Recruitment Status:

Active, not recruiting

Sponsor:

University of Michigan Rogel Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

University of Michigan Hospital and Health Systems
Ann Arbor Michigan, 48109, United States
Wayne State University/Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Henry Ford Hospital
Detroit Michigan, 48202, United States
Urologic Consultants
Grand Rapids Michigan, 49503, United States
Urology Associates of Grand Rapids
Grand Rapids Michigan, 49503, United States
Michigan Urological Clinic
Grand Rapids Michigan, 49546, United States
Spectrum Health Medical Group- Urology
Grand Rapids Michigan, 49546, United States
Urology Surgeons, PC
Grand Rapids Michigan, 49546, United States
Comprehensive Medical Center, PLLC
Royal Oak Michigan, 48073, United States
Tri-City Urology
Saginaw Michigan, 48601, United States
Bay Area Urology Associates, PC
Traverse City Michigan, 49684, United States
Michigan Institute of Urology-Town Center
Troy Michigan, 48084, United States
IHA Urology at St. Joe's Ann Arbor
Ypsilanti Michigan, 48197, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Estimated Enrollment:

356

Study ID:

NCT02783950

Recruitment Status:

Active, not recruiting

Sponsor:


University of Michigan Rogel Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.